Achieve life sciences, inc. (ACHV)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating Activities:
Net loss

-16,395

-12,687

-10,583

-

-

-

-

-

-

-

-

Net loss

-

-

-

-20,129

-16,801

-26,240

-31,849

-21,098

-14,673

-12,584

-5,476

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on warrants [note 7 and note 11[e]]

-

-

-150

-873

-1,897

-3,741

-3,208

-4,459

-7,388

-96

-

Warrant issuance costs

-

-

-

-

-

531

-

-

-

1,027

-

Depreciation

31

60

59

188

244

223

227

100

75

52

50

Amortization

223

222

223

-

-

-

-

-

-

-

-

Asset impairment charge

-

-

-

202

-

-

-

-

-

-

-

Stock-based compensation [note 6 [c] and note 6 [d]]

1,201

854

348

1,649

2,328

3,860

2,834

2,175

1,188

642

380

Cumulative adjustment on adoption of lease standard

3

-

-

-

-

-

-

-

-

-

-

Deferred income tax (recovery) [note 2 and 5]

-

-

-3,051

-

-

-

-

-

-

-

-

Bargain purchase gain [note 2]

-

-

1,272

-

-

-

-

-

-

-

-

Loss on disposition [note 2]

-

-

-8,610

-

-

-

-

-

-

-

-

Contingent value rights recovery [note 2]

-

-

200

-

-

-

-

-

-

-

-

Restructuring gain [note 8]

-

-

-

-

-

3,517

-

-

-

-

-

Restructuring gain [note 7 and note 15]

-

-

-

-

-

-

-

-1,657

-

4,038

3,951

Gain on non-monetary transaction [note 9]

-

-

-

-

-

-

-

151

-

-

-

Changes in operating assets and liabilities:
Interest receivable

-

-

-

-79

-2

-105

-109

-36

-211

494

-

Amounts receivable

1

-2

9

464

-5,662

-2,981

7,943

265

-201

-2,379

2,955

Prepaid expenses and other assets

-195

343

1,349

-1,057

-1,167

-3,944

1,974

3,037

-1,278

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

1,763

136

Accounts payable

715

-69

118

778

1,271

-67

-1,190

-175

1,222

-

-

Accrued liabilities other

-328

310

-2,185

1,801

-222

363

41

269

-

-

-

Accrued clinical liabilities

-812

322

877

-

-

-

-

-

-

-

-

Accrued compensation

-52

710

458

-

-

-

-

-

-

-

-

Accrued clinical liabilities

-

-

-

-6,551

-3,714

2,178

7,563

-

247

-

-

Accrued clinical liabilities

-

-

-

-

-

-

-

3,150

-

-

-

Accrued compensation

-

-

-

-1,079

-66

-372

164

589

855

-

-

Salaries payable

-

-

-1,028

-

-

-

-

-

-

-

-

Investment tax credit recoverable

-

-

-

-

-

-

-

-

-

-

-1,090

Restricted cash

-

-

-

-

21

-63

-

-63

-125

502

-

Excess lease liability

-

-

-

-

-194

-785

-680

-795

-407

-

-

Other Assets

-

-

-

-

-

-

-

-

-

4

12

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-13,560

12,200

Excess lease liability [note 6]

-

-

-

-

-

-

-

-

-

1,069

741

Lease obligation [note 7]

-10

4

-27

51

-100

84

21

-33

-154

-

-

Proceeds from the exercise of stock options

-

-

-

-

14

30

10

462

219

-

-

Net cash used in operating activities

-15,216

-10,623

-9,107

-

-

-

-

-

-20,263

-26,840

34,878

Financing Activities:
Proceeds from share subscription

-

-

64

-

-

22,372

-

53,777

-

-

17,206

Proceeds from exercise of warrants, net of issuance costs

4,199

1,324

-

-

-

-

-

-

-

-

-

Lease termination fees

-

-

-

-1,250

-2,000

3,250

-

-

-

-

-

Deferred collaboration revenue [note 3]

-

-

-

-5,040

5,040

-

-

-18,271

-3,351

-4,906

26,527

Net cash used in operating activities

-

-

-

-29,683

-9,101

-17,308

-35,927

-43,493

-

-

-

Taxes paid related to net share settlement of equity awards

-

-

5

2

52

29

-

-

-

-

-

Purchase of investments

-

-

-

36,504

24,368

19,446

31,696

-

-

-

-

Cash paid on fractional shares eliminated on reverse share split

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

824

141

Issuance of warrants, net of warrant issuance costs

-

-

-

-

-

-

-

-

-

14,338

-

Issuance of common shares, net of share issue costs

-

-

-

-

-

-

-

-

-

-32,319

-

Net cash used in financing activities

17,325

19,757

2,001

-

-

-

-

-

219

47,481

17,347

Investing Activities:
Cash received on reverse takeover of OncoGenex

-

-

12,648

-

-

-

-

-

-

-

-

Purchase of investments

-

-

-

-

-

-

-

110,443

75,147

93,018

4,036

Proceeds from sale of investments

-

-

-

-

1,003

-

1,000

7,365

12,656

33,960

6,280

Proceeds from maturities of investments

-

-

-

47,158

21,659

24,894

63,375

82,181

87,638

-

-

Purchase of property and equipment

53

46

-

46

371

82

253

291

79

68

15

Net cash provided by financing activities

-

-

-

-2

17,591

25,247

10

54,239

-

-

-

Proceeds on disposal of assets

-

10

-

-

-

-

-

-

-

-

-

Purchase of investments

25

5,539

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

5,114

450

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

10,608

-2,077

5,366

32,426

-21,188

-

-

-

Net cash provided by (used in) investing activities

5,036

-5,125

12,648

-

-

-

-

-

25,068

-59,126

2,229

Effect of exchange rate changes on cash

4

-

-1

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-1

9

-

-40

-33

-21

Net increase (decrease) in cash, cash equivalents and restricted cash

7,149

4,009

5,541

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-19,077

6,413

13,304

-3,482

-10,442

4,984

-38,518

54,433

Property and equipment received and accrued but not yet paid

-

-

-

-

218

-

-

-

-

-

-

Property and equipment acquired under lease obligation

-

-

-

-

-

-

24

-

89

-

65

October 2018 Registered Direct Offering [Member]
Proceeds from purchase agreement and registered direct offering, net of issuance costs

-

4,960

-

-

-

-

-

-

-

-

-

LPC [Member]
Proceeds from purchase agreement and registered direct offering, net of issuance costs

792

1,279

1,942

-

-

-

-

-

-

-

-

June 2018 Public Offering [Member]
Proceeds from public offering, net of issuance costs

-

12,194

-

-

-

-

-

-

-

-

-

December 2019 Public Offering [Member]
Proceeds from public offering, net of issuance costs

12,334

-

-

-

-

-

-

-

-

-

-